Efficacy and Safety of Pantoprazole and Ranitidine in Treating Patients with Gastroesophageal Reflux Disease:A Meta-analysis
10.3870/j.issn.1004-0781.2016.04.020
- VernacularTitle:泮托拉唑与雷尼替丁治疗胃食管反流病疗效和安全性的Meta分析?
- Author:
Jiaxing ZHANG
;
Juan XIE
;
Zhongyuan WANG
;
Qi CHEN
;
Ling GAO
;
Lei LUO
;
Lianhua LI
;
Shijuan XIONG
;
Changcheng SHENG
- Publication Type:Journal Article
- Keywords:
Pantoprazole;
Ranitidine;
Gastroesophageal reflux disease;
Meta-analysis
- From:
Herald of Medicine
2016;35(4):404-410
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically review the effectiveness and safety of pantoprazole ( PAN ) vs. ranitidine (RAN) for patients with gastroesophageal reflux disease (GERD). Methods PubMed,Medline,EMbase,The Cochrane Library and three Chinese literature databases (CNKI,VIP and Wan fang) were retrieveed.Randomized controlled trials (RCTs) which compared the clinical outcomes of PAN group vs. RAN group for GERD were included. Two reviewers independently screened literatures in accordance with the inclusion and exclusion criteria, extracted the data and assessed the methodological quality of included studies.Then,meta-analysis was performed using RevMan 5.2 software. Results A total of 8 RCTs involving 1 590 patients were included.The results of meta-analysis showed that the PAN group was significantly superior to RAN group in terms of the healing rates and the relief rates of chief symptom for GERD of gradeⅠ-Ⅲ. While there was no significant difference in the incidence of adverse events between the two groups [GradeⅠ,RR=1.17,95%CI (0.80,1.70),P=0.43;GradeⅡorⅢ, RR=0.76,95%CI (0.43,1.36);P=0.36]. Conclusion Current evidence indicates that,pantoprazole is more effective than ranitidine for GERD of grade Ⅰ-Ⅲ,but both treatments are safe and well tolerated.
